Targeting nerve growth factor (NGF) for pain management: What does the future hold for NGF antagonists?

Drugs

Volumn 74, Issue 6, 2014, Pages 619-626

  Bannwarth, Bernard ^a,b   Kostine, Marie ^a  

^a HÔPITAL PELLEGRIN   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 110; ANALGESIC AGENT; FASINUMAB; FULRANUMAB; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; TANEZUMAB; UNCLASSIFIED DRUG;

ANALGESIA; CHRONIC PAIN; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; FUTUROLOGY; HIP OSTEOARTHRITIS; JOINT DESTRUCTION; KNEE OSTEOARTHRITIS; LOW BACK PAIN; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; PERIPHERAL NEUROPATHY; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); HUMAN; PAIN; PATHOPHYSIOLOGY; UNITED STATES;

ANALGESICS; ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; NERVE GROWTH FACTOR; PAIN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84899992954     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0208-6     Document Type: Review

References (31)

1. Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet. 2011;377:2226-35.
2. Bannwarth B, Kostine M, Shipley E. Nonspecific low back pain: assessment of available medications. Joint Bone Spine. 2012;79:134-6.
3. Woodcock J, Witter J, Dionne RA. Stimulating the development of mechanism-based, individualized pain therapies. Nat Rev Drug Discov. 2007;6:703-10.
4. Eibl JK, Strasser BC, Ross GM. Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor. Neurochem Int. 2012;61:1266-75.
5. Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharm Sci. 2006;27:85-91.
6. Watson JJ, Allen SJ, Drawbarn D. Targeting nerve growth factor in pain. What is the therapeutic potential? Biodrugs. 2008;22:349-59.
7. Seidel MF, Herguijuela M, Forkert R, et al. Nerve growth factor in rheumatic diseases. Semin Arthritis Rheum. 2010;40:109-26.
8. Seidel MF, Wise BL, Lane NE. Nerve growth factor: an update on the science and therapy. Osteoarthritis Cartilage. 2013;21:1223-8.
9. Garber K. Fate of novel painkiller mAbs hangs in balance. Nat Biotechnol. 2011;29:173-4.
10. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363:1521-31.
11. Brown MT, Murphy FT, Radin DM, et al. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J Pain. 2012;13:790-8.
12. Brown MT, Murphy FT, Radin DM, et al. Tanezumab reduces osteoarthritic hip pain. Results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum. 2013;65:1795-803.
13. Spierings ELH, Fidelholtz J, Wolfram G, et al. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain. 2013;154:1603-12.
14. Balanescu AR, Feist E, Wolfram G, et al. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis. 2013 (in press).
15. Yazici Y, Ekman EF, Greenberg HS, et al. Efficacy of tanezumab compared with non-steroidal anti-inflammatory drugs in patients with knee or hip osteoarthritis (NCT00809354) [abstract]. Arthritis Rheum. 2011;63(Suppl 10):S828.
16. Tive L, Dabezies EJ, Fountaine RJ, et al. Long-term safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis (NCT00994890) [abstract]. Arthritis Rheum. 2013;65(Suppl 10):S911-2.
17. Schnitzer TJ, Lane NE, Birbara C, et al. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage. 2011;19:639-46.
18. Sanga P, Katz N, Polverejan E, et al. Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain. Pain. 2013;154:1910-9.
19. Tiseo P, Kivitz AJ, Ervin JE, et al. REGN475/SAR164877, a nerve growth factor inhibitor, in osteoarthritis patients with moderate to severe knee pain [abstract]. Arthritis Rheum. 2010;62(Suppl 10):S710.
20. Katz N, Borenstein DG, Birbara C, et al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain. 2011;152:2248-58.
21. Kivitz AJ, Gimbel JS, Bramson C, et al. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain. 2013;154:1009-21.
22. Sanga P, Karcher K, Wang K, et al. Efficacy, safety, and tolerability of fulranumab in treatment of patients with moderate-to-severe chronic low back pain [abstract]. J Pain. 2011;12(Suppl 4):P53.
23. Food and Drug Administration Center for Drug Evaluation and Research. Arthritis Advisory Committee Meeting; 2012. http://www.fda.gov/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/ ucm286552.htm, http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM301302.pdf (Accessed 28 Dec 2013).
24. Evans RJ, Moldwin RM, Cossons N, et al. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2001;185:1716-21.
25. Nickel JC, Atkinson G, Krieger JN, et al. Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2012;80:1105-10.
26. Wang H, Romano G, Frustaci ME, et al. Analgesic efficacy of fulranumab in patients with painful diabetic peripheral neuropathy in a randomized, placebo-controlled, double-blind study [abstract]. J Neurol Sci. 2013;333(Suppl 1):e522-3.
27. Bramson C, Herrmann D, Biton V, et al. Efficacy and safety of subcutaneous tanezumab in patients with pain related to diabetic peripheral neuropathy (NCT01087203) [abstract]. J Pain. 2013;14(Suppl 4):S68.
28. Romano G, Wang H, Ritz J, et al. Analgesic efficacy of fulranumab in patients with neuropathic pain in a randomized, placebo-controlled, double blind study. 14th World Congress on Pain, Milano; 2012, abstract PT452. http://www.abstracts2view.com/iasp/view.php?nu=107827&type=abstract (Accessed 28 Dec 2013).
29. Holmes D. Anti-NGF painkillers back on track? Nat Rev Drug Discov. 2012;11:337-8.
30. Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the Arthritis Advisory Committee Meeting; 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ArthritisAdvisoryCommittee/UCM307879.pdf (Accessed 15 Jan 2014).
31. Moss AC, Brinks V, Carpenter JF. Immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. Aliment Pharmacol Ther. 2013;38:1188-97.